CANCER LEADERSHIP COUNCIL
    
    April 23, 2013
       
       CANCER LEADERSHIP COUNCIL
       STATEMENT ON SEQUESTRATION AND CANCER CARE
        REIMBURSEMENT
      
    
      More than half of all cancer diagnoses in the United
    States occur among Medicare beneficiaries, and reliable access to
    outstanding cancer care depends on a smoothly functioning Medicare
    payment system.   The Cancer Leadership Council, a
    coalition of cancer patients, physicians, and researchers, supports
    a Medicare payment system that rewards the delivery of quality care
    and operates without disruption.
    
    The Cancer Leadership Council supports the efforts of a bipartisan
    group of Members of Congress to obtain information from the Centers
    for Medicare & Medicaid Services (CMS) about the impact of the
    sequestration cut on patient access to care and to ascertain the
    flexibility of CMS in implementation of sequestration.  
    
    Cancer Leadership Council organizations have mobilized their patient
    services programs, information networks, and outreach programs to
    detect possible barriers to care for cancer patients and also to
    provide assistance to any patients who may experience difficulties
    in obtaining the care they need.  
    
    The sequester has also directed attention to the weaknesses and
    inappropriate incentives in Medicare reimbursement for cancer
    care.  The Cancer Leadership Council urges Congress, even as it
    considers the impact of sequestration and solutions to any
    disruptions in care, to consider these core principles for Medicare
    cancer care payment reform:
    
      - Medicare reimbursement should support: 1) physician-patient
        communication for treatment planning, 2) coordination of symptom
        management and active treatment, 3) delivery of evidence-based
        cancer care, and 4) the transition from treatment to
        survivorship monitoring and follow-up care.  
 
      - Physician services for quality cancer care should be supported
        by direct reimbursement and not through margins on drugs. 
        
       
      - Current systems for acquisition and payment of cancer drugs,
        including average sales price-based reimbursement in Medicare
        Part B and the 340B drug discounting system, should be evaluated
        for their significant impact on cancer patients, including the
        quality of care they receive and the site at which they receive
        care, and for their effects on the overall cancer care delivery
        system.
 
    
    Reform of the Medicare cancer care payment system is an urgent
    matter for current beneficiaries and for baby-boomers soon to join
    their ranks and must focus on creation of a system of
    patient-centered care that is appropriately reimbursed. 
    
    CANCER LEADERSHIP COUNCIL
    
    American Cancer Society Cancer Action Network
    Bladder Cancer Advocacy Network
    Cancer Support Community
    Fight Colorectal Cancer 
    International Myeloma Foundation
    LIVESTRONG Foundation
    Leukemia & Lymphoma Society
    Lymphoma Research Foundation
    National Coalition for Cancer Survivorship
    National Lung Cancer Partnership
    Ovarian Cancer National Alliance
    Pancreatic Cancer Action Network
    Prevent Cancer Foundation
    Sarcoma Foundation of America
    Susan G. Komen for the Cure Advocacy Alliance
    Us TOO International Prostate Cancer Education and Support Network